PharmaTelevision - SeraCare’s Corporate Turnaround

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: SeraCare’s Corporate Turnaround

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Sue Vogt, CEO of SeraCare Life Sciences, backed by a new management team, has, over the past 12-18 months, brought the company back from bankruptcy and restored the credibility that had been lost. In this interview, she explains how she managed to achieve this, using the recent re-listing of SeraCare on NASDAQ as an example of this turnaround.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

SeraCare serving the Global Life Sciences Community

Fintan Walton:

Hello and welcome to PharmaVentures business review here in San Francisco. On this show I have Sue Vogt who is the CEO of SeraCare life sciences Incorporated based here in the US. Welcome to the show.

Sue Vogt:

Thank you.

Fintan Walton:

Sue Vogt you run an interesting company it is a company that has both products and services and you joined that company just about 18 months ago. Could you a tell us a little bit about what the what the business actually is of SeraCare?

Sue Vogt:

Sure. we talk about SeraCare as being the picks and shovels for the life science industry. We are really a tools provider and we have a part of our business which is around services to the life science industry and then another part of our business which is specific products that are used by diagnostic and pharmaceutical manufacturers and developers.

Fintan Walton:

Right so specifically what are those products? 00:01:22

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Sue Vogt

President and Chief Executive Officer

Sue Vogt has been president, chief executive officer, and a board member at SeraCare since 2006. She was previously president of the biopharmaceutical division of Millipore Corporation, where she led a $520 million division. Prior, she served as vice president and general manager of the laboratory water division at Millipore. Sue Vogt holds an MBA from Boston University and a BA from Brown University.

SeraCare Life Sciences

SeraCare Life Sciences, Inc. (SeraCare) serves the global life sciences industry by providing products and services to facilitate the discovery, development and production of human and animal diagnostics and therapeutics. The Company's portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. The Company's business is divided into two segments: Diagnostic Biopharmaceutical Products and BioServices. SeraCare's Diagnostic and Biopharmaceutical Products segment includes two types of products: controls and panels, which include the manufacture of products used for quality control of infectious disease testing in hospital and clinical testing laboratories and blood banks, and by in vitro diagnostic (IVD) manufacturers, and reagents and bioprocessing products, which include the manufacture and supply of biological materials used in the research, development and manufacturing of human and animal diagnostics, therapeutics and vaccines. The BioServices segment includes biobanking, sample processing and testing services for research and clinical trials, and contract research services in molecular biology, virology, immunology and biochemistry.